Compare Davita Inc (DVA) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nike Inc — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Nike Inc trades at $41.23 (market cap $62.47B). The key difference: Nike Inc is far larger — about 5.3× Davita Inc's market cap, and Nike Inc pays a 3.89% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | NKE | |
|---|---|---|
Market Cap | $11.72B | $62.47B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $79.17 |
52-Week Low | $103.87 | $40.75 |
Enterprise Value | $24.44B | $64.48B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Nike (NKE) trades at $41.32, down 0.91% on the day, reflecting near-term pressure amid a bearish technical signal. The stock shows strong profitability with a 42.91% gross margin and 22.14% ROE, but revenue declined to $46.31B in 2025. Recent quarters have consistently beaten EPS estimates, with Q1 2026 EPS of $0.72 significantly exceeding expectations. Analysts maintain a consensus Buy rating with a $50.45 price target, indicating potential upside from current levels.
The outlook balances solid brand strength and earnings beats against revenue headwinds and competitive pressures. Investment opportunity lies in valuation discount to analyst targets and operational discipline, but risks include sluggish demand in key markets like China and margin compression from promotional activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
